Maseru, Oct. 28 — World Health Organisation (WHO) published the preferred product characteristics (PPC) of blood-based biomarker diagnostics for Alzheimer disease (AD).
According to the health organization, the PPC aims to inform the development of blood-based biomarker diagnostics or tests for the disease by ensuring that tests achieve optimal clinical performance and will be suitable for future use in a range of settings including low and middle income countries, including Lesotho.
It further states that the primary audience for this PPC includes entities intending to eventually seek WHO policy recommendations and prequalification, adding that it offers guidance to funders, researchers, product developers and regulatory agencies in the development and implementation of diagnostic tools using blood-based biomarkers for AD. . .
